The last peptide wave helped create trillion-dollar giants like Eli
Lilly and Novo Nordisk.
GLP-1 drugs - Ozempic, Wegovy, Mounjaro, Zepbound - turned peptides
into the best-selling drug class in pharma in 2024, overtaking cancer
immunotherapies.
Now, a new FDA shift could open the door to a…
See More from Washington Examiner